Fosun Pharma subsidiary's ketoprofen patch approved for clinical trial

Shanghai Zhaohui Pharmaceutical Company Limited, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of its Ketoprofen Patch. Zhaohui Pharma intends to initiate Phase III clinical trials for the drug in China. The Ketoprofen Patch is designed for analgesic and anti-inflammatory effects, targeting conditions such as lower back pain, osteoarthritis, frozen shoulder, tendonitis, and muscle pain, as well as local analgesia for rheumatoid arthritis.

As of October 2025, Fosun Pharma's Group has invested approximately RMB0.96 million in the research and development of the Ketoprofen Patch. Market data from IQVIA CHPA indicates that sales of Ketoprofen Preparations in China reached approximately RMB91.16 million in 2024, highlighting the potential market for the drug.

The company cautioned investors about the inherent risks in drug R&D, noting that clinical trials are subject to regulatory approvals and potential termination due to safety or efficacy issues. The R&D and launch of drugs are long-term processes with various uncertainties, and investors are advised to consider these investment risks.